BioVersys AG (SWX:BIOV)
Switzerland
· Delayed Price · Currency is CHF
29.90
+0.40 (1.36%)
At close: Apr 28, 2026
BioVersys AG Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Operating Revenue | 0.8 | - | - |
| Other Revenue | 2.38 | 1.21 | 1.14 |
| Revenue | 3.18 | 1.21 | 1.14 |
| Revenue Growth (YoY) | 161.75% | 6.50% | - |
| Gross Profit | 3.18 | 1.21 | 1.14 |
| Selling, General & Admin | 6.73 | 6.99 | 4.02 |
| Research & Development | 16.5 | 12.95 | 14.83 |
| Other Operating Expenses | -0.09 | - | - |
| Operating Expenses | 23.14 | 19.94 | 18.84 |
| Operating Income | -19.96 | -18.72 | -17.7 |
| Interest Expense | -1.08 | -1.04 | -0.7 |
| Interest & Investment Income | 0.05 | 0.5 | 0.48 |
| Currency Exchange Gain (Loss) | -0.01 | 0.13 | -0.16 |
| Other Non Operating Income (Expenses) | -0.81 | 0.42 | -0.22 |
| Pretax Income | -21.81 | -18.72 | -18.3 |
| Income Tax Expense | 0.02 | - | - |
| Net Income | -21.83 | -18.72 | -18.3 |
| Net Income to Common | -21.83 | -18.72 | -18.3 |
| Shares Outstanding (Basic) | 6 | 3 | 3 |
| Shares Outstanding (Diluted) | 6 | 3 | 3 |
| Shares Change (YoY) | 68.49% | 11.60% | - |
| EPS (Basic) | -3.89 | -5.62 | -6.13 |
| EPS (Diluted) | -3.89 | -5.62 | -6.13 |
| Free Cash Flow | -22.16 | -15.61 | -11.7 |
| Free Cash Flow Per Share | -3.95 | -4.68 | -3.92 |
| Gross Margin | 100.00% | 100.00% | 100.00% |
| Operating Margin | -628.76% | -1543.45% | -1554.17% |
| Profit Margin | -687.56% | -1543.20% | -1606.76% |
| Free Cash Flow Margin | -698.02% | -1287.06% | -1027.57% |
| EBITDA | -19.89 | -18.66 | -17.65 |
| D&A For EBITDA | 0.07 | 0.06 | 0.06 |
| EBIT | -19.96 | -18.72 | -17.7 |
| Revenue as Reported | 3.27 | 1.21 | 1.14 |
Source: S&P Capital IQ. Standard template.
Financial Sources.